CB1 Receptors in Human Brown Adipose Tissue
Launched by TURKU UNIVERSITY HOSPITAL · Oct 19, 2016
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
Endocannabinoids have an important role in regulating energy balance and metabolism. Cannabinoid 1 receptors (CB1) are found in several tissues such as brown adipose tissue (BAT). Endocannabinoids and CB1 receptors participate in the control of lipid and glucose metabolism, and blockage of CB1 receptors has been found to improve metabolic factors linked to obesity and cardiovascular disease, making CB1 antagonists potential drugs against obesity and diabetes.
In this study the investigators use a PET radiotracer \[18F\]FMPEP-d2, which binds to CB1 receptors in vivo, to quantify the CB1 rec...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Healthy volunteer
- • Group 1: BMI 20-26 kg/m2, Group2: BMI 27-40 kg/m2
- Exclusion Criteria:
- • BMI \< 20 kg/m2or BMI \> 40 kg/m2
- • Any chronic disease that could affect the study outcome, including medicated type 2 diabetes
- • Mental disorder or poor compliance
- • Eating disorder or excessive use of alcohol, tobacco smoking or drug use
- • Past dose of radiation
- • Presence of any ferromagnetic objects that would make MR imaging contraindicated
- • Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results
About Turku University Hospital
Turku University Hospital (TYKS) is a leading academic medical center located in Turku, Finland, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a key institution within the University of Turku, TYKS integrates cutting-edge medical education with state-of-the-art clinical services, offering a broad spectrum of specialized care. The hospital actively participates in clinical trials, facilitating the translation of scientific discoveries into practical treatments, and enhancing patient outcomes. With a multidisciplinary approach and a focus on collaboration, TYKS aims to contribute significantly to the global medical community through its rigorous research initiatives and commitment to patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Turku, , Finland
Patients applied
Trial Officials
Pirjo Nuutila, M.D., Ph.D.
Principal Investigator
Turku PET Centre (Turku University Hospital)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials